Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association
Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and
kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic …
kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic …
Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies
HC Kenny, ED Abel - Circulation research, 2019 - Am Heart Assoc
Patients with diabetes mellitus have> 2× the risk for developing heart failure (HF; HF with
reduced ejection fraction and HF with preserved ejection fraction). Cardiovascular …
reduced ejection fraction and HF with preserved ejection fraction). Cardiovascular …
Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not …
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …
morbidity and mortality in patients with established disease. Secular trends in the …
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
treatments for type 2 diabetes, lowering glycated haemoglobin (HbA 1c) and weight, but are …
treatments for type 2 diabetes, lowering glycated haemoglobin (HbA 1c) and weight, but are …
PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes
VR Aroda, J Rosenstock, Y Terauchi, Y Altuntas… - Diabetes …, 2019 - Am Diabetes Assoc
OBJECTIVE This trial compared the efficacy and safety of the first oral glucagon-like peptide
1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with …
1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with …
Lifestyle factors, self-management and patient empowerment in diabetes care
E Lambrinou, TB Hansen… - European journal of …, 2019 - journals.sagepub.com
Although management of diabetes mellitus is improving, inadequately managed cases still
exist. Prevention of diabetes mellitus requires an integrated and holistic approach based on …
exist. Prevention of diabetes mellitus requires an integrated and holistic approach based on …
Clinical use of DPP-4 inhibitors
B Gallwitz - Frontiers in endocrinology, 2019 - frontiersin.org
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate
insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 …
insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 …
Major microbiota dysbiosis in severe obesity: fate after bariatric surgery
Objectives Decreased gut microbial gene richness (MGR) and compositional changes are
associated with adverse metabolism in overweight or moderate obesity, but lack …
associated with adverse metabolism in overweight or moderate obesity, but lack …
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
O Mosenzon, TM Blicher, S Rosenlund… - The lancet Diabetes & …, 2019 - thelancet.com
Background Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor
agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly …
agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly …
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase …
Background Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-
1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the …
1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the …